Table 2. Clinical responses to tocilizumab at weeks 24 and 48.

Efficacy measure		25(OH)D ≥ 30 ng/mL (n = 34)	25(OH)D < 30 ng/mL (n = 64)	P value
At week 24
	DAS28 reduction, %	64.6 ± 15.5	52.7 ± 20.7	0.004
	Low DAS28 (DAS28 ≤ 3.2)	31 (91.2)	45 (70.3)	0.018
	Remission (DAS28 ≤ 2.6)	28 (82.4)	37 (57.8)	0.014
	Clinically significant reduction ≥ 1.2	33 (97.1)	59 (92.2)	0.661
At week 48		(n = 25)	(n = 50)
	DAS28 reduction, %	67.6 ± 13.9	59.8 ± 16.4	0.044
	Low DAS28 (DAS28 ≤ 3.2)	24 (96.0)	43 (86.0)	0.256
	Remission (DAS28 ≤ 2.6)	23 (92.0)	35 (70.0)	0.032
	Clinically significant reduction ≥ 1.2	25 (100.0)	49 (98.0)	1.000

Data are presented as number (%) or mean ± standard deviation.

DAS = disease activity score.